[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538466":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":47,"centralContacts":52,"locations":58,"responsibleParty":72,"collaborators":33,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":33,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":33,"enrollmentInfo":83,"targetDuration":33,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":33,"overallStatus":60,"whyStopped":33,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,16,22],{"label":9,"type":10,"description":11,"interventionNames":12},"AD-224A","EXPERIMENTAL","AD-224A+Placebo of AD-224B+Placebo of AD-224C",[13,14,15],"Drug: AD-224A","Drug: Placebo of AD-224B","Drug: Placebo of AD-224C",{"label":17,"type":10,"description":18,"interventionNames":19},"AD-224B","Placebo of AD-224A+AD-224B+Placebo of AD-224C",[20,21,15],"Drug: AD-224B","Drug: Placebo of AD-224A",{"label":23,"type":24,"description":25,"interventionNames":26},"AD-224C","ACTIVE_COMPARATOR","Placebo of AD-224A+Placebo of AD-224B+AD-224C",[27,21,14],"Drug: AD-224C",[29,34,36,38,41,44],{"type":30,"name":9,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","PO, Once daily, 8weeks",[9],null,{"type":30,"name":17,"description":31,"armGroupLabels":35,"otherNames":33},[17],{"type":30,"name":23,"description":31,"armGroupLabels":37,"otherNames":33},[23],{"type":30,"name":39,"description":31,"armGroupLabels":40,"otherNames":33},"Placebo of AD-224A",[17,23],{"type":30,"name":42,"description":31,"armGroupLabels":43,"otherNames":33},"Placebo of AD-224B",[9,23],{"type":30,"name":45,"description":31,"armGroupLabels":46,"otherNames":33},"Placebo of AD-224C",[9,17],[48],{"name":49,"affiliation":50,"role":51},"InHo Chae, M.D., Ph.D","Seoul National University Bundang Hospital","PRINCIPAL_INVESTIGATOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":33,"email":57},"JeongEun Park","CONTACT","+82-31-891-6989","parkje@addpharma.co.kr",[59],{"facility":50,"status":60,"city":61,"state":33,"zip":33,"country":62,"countryCode":33,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Seongnam-si","South Korea",{"type":64,"coordinates":65},"Point",[66,67],127.13778,37.43861,{"lat":67,"lon":66},[70],{"name":71,"role":55,"phone":33,"phoneExt":33,"email":33},"InHo Chae",{"type":73,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100538466","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-ad-224-100538466",false,"NCT06291207","A Study to Evaluate the Efficacy and Safety of AD-224","A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients with Essential Hypertension","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with Essential Hypertension\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patient with Secondary Hypertension\n* Other exclusions applied","ALL","19 Years",{"count":84,"type":85},252,"ESTIMATED","INTERVENTIONAL",[88],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of AD-224",[91],"Hypertension,Essential","2025-02-02",{"date":94,"type":95},"2025-02-04","ACTUAL",{"date":97,"type":95},"2024-04-15",{"date":99,"type":85},"2025-07",{"name":5,"class":6},1]